A LinkedIn post from 4BIO Capital highlights two senior appointments, with the promotion of Therese Liechtenstein to Partner and the addition of Tetsuyuki Maruyama as Venture Partner. The post underscores ongoing efforts to deepen investment and scientific leadership in biotech and precision therapies.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to the post, Liechtenstein has been involved in shaping 4BIO’s investment strategy since 2024, drawing on experience that includes Actithera’s oversubscribed $75.5M Series A and Araris Biotech AG’s sale to Taiho Pharmaceutical for up to $1.14B. This track record suggests a focus on deal-making capability and value creation across both early-stage financing and strategic exits.
The post also notes that Maruyama brings more than two decades of global R&D leadership in neuroscience and translational drug discovery, with senior roles at Takeda, GSK, and SV Health Investors’ Dementia Discovery Fund. His remit as Venture Partner is described as supporting 4BIO’s efforts to translate innovative Japanese technologies into precision therapies.
For investors, these appointments may indicate an intention to strengthen 4BIO’s edge in sourcing and building high-potential biotech assets, particularly in neuroscience and precision medicine. The emphasis on experience with large financings, M&A outcomes, and Japanese innovation could enhance the firm’s deal pipeline, geographic reach, and ability to back assets attractive to strategic pharma buyers over the medium term.